First-in-Class HCV Drug Licensed by Novartis
Share
Follow Us
The Editors at Hepatitis Central
February 16, 2010
Novartis licenses alisporivir, a new drug that is currently in Phase IIb development for the treatment of Hepatitis C.
Novartis licenses Hepatitis C drug
Feb. 9, 2010
By Steve Goldstein
LONDON (MarketWatch) — Novartis /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 53.73, +0.02, +0.04%) /quotes/comstock/06p!novn (CH:NOVN 57.80, 0.00, 0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
Continue reading this entire article:
http://www.marketwatch.com/story/novartis-licenses-hepatitis-c-drug-2010-02-09
